European Biotech Acquisition Current Cash

European Biotech Acquisition's current cash stands at $310K as of December 2022. That compares with $870K in the prior-year period — down 64.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

European Biotech Acquisition reported $310K in current cash versus $870K a year earlier — a 64.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $870K in the prior-year period — down 64.5% year over year. Sustained growth in current cash can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how European Biotech Acquisition's current cash evolved across reporting periods, while the comparison chart places EBAC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.